Back to Search

ADEL KARDOSH, M.D.

M.D.

Medical Oncology Physician

NPI: 1235400177IndividualAccepts Medicare

Specialties, Licenses & Credentials

Student in an Organized Health Care Education/Training Program

Student in an Organized Health Care Education/Training Program

Code: 390200000X

113847(CA)
Medical Oncology PhysicianPrimary

Internal Medicine — Medical Oncology

Code: 207RX0202X

MD188428(OR)

CMS Specialties

PrimaryMEDICAL ONCOLOGY

Education

UNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL OF MEDICINE

Class of 2011

Research & Publications (16)

Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
PMID 18245486·Cancer Res·2008
7-preclinical
Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib.
PMID 17440835·J Biomed Sci·2007
8-other
Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib.
PMID 16123214·Blood·2005
8-other
Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo.
PMID 15846081·Cancer Biol Ther·2005
4-observational
Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.
PMID 14726653·Cancer Biol Ther·2004
8-other
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
PMID 19190249·Blood·2009
7-preclinical
Celecoxib transiently inhibits cellular protein synthesis.
PMID 17920040·Biochem Pharmacol·2008
7-preclinical
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro.
PMID 18485224·Mol Cancer·2008
8-other
HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.
PMID 18006837·Cancer Res·2007
7-preclinical
Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib.
PMID 17431104·Mol Cancer Ther·2007
7-preclinical
Glioma-associated endothelial cells show evidence of replicative senescence.
PMID 17291495·Exp Cell Res·2007
8-other
Potential misidentification of cyclooxygenase-2 by Western blot analysis and prevention through the inclusion of appropriate controls.
PMID 17284780·Mol Biotechnol·2006
4-observational
Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model.
PMID 17134116·Neurosurg Focus·2006
7-preclinical
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
PMID 16709026·Neurosurg Focus·2006
7-preclinical
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.
PMID 16707021·Mol Cancer·2006
4-observational
Suppression of the transformed phenotype and induction of differentiation-like characteristics in cultured ovarian tumor cells by chronic treatment with progesterone.
PMID 14639655·Mol Carcinog·2003
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
3181 SW SAM JACKSON PARK RD
PORTLAND, OR 97239

Location

Practice Location

3181 SW SAM JACKSON PARK RD, PORTLAND, OR
(503) 494-8534

Quick Facts

NPI
1235400177
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
2
Locations
1
Years in Practice
15
Publications
16

Are you this provider?

Claim Your Profile